Helix BioPharma Corp. Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Board has authorized a process to explore a partnership, alliance, joint development or licensing transaction of its L-DOS47 drug product candidate
(the “Transaction”).  Today’s announcement is part of Helix’s continuing efforts to effectively allocate resources and capital, and create value for its shareholders.